AFG
NBIX icon

Atomi Financial Group’s Neurocrine Biosciences NBIX Stock Holding History

Atomi Financial Group’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$318K Buy
1,888
+112
+6% +$16.6K 0.01% 999
2026
Q1 		$234K Sell
1,776
-81
-4% -$10.7K 0.01% 1080
2025
Q4 		$263K Buy
1,857
+13
+0.7% +$1.88K 0.01% 1006
2025
Q3 		$259K Buy
1,844
+6
+0.3% +$813 0.01% 972
2025
Q2 		$231K Buy
+1,838
New +$211K 0.01% 974

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Atomi Financial Group's NBIX Position: Q2 2026 in Review

Atomi Financial Group increased its Neurocrine Biosciences (NBIX) stake by 6.3% in Q2 2026, buying an estimated $16.6K and bringing the position to 1,888 shares worth $318K. The position accounts for 0.01% of the portfolio, ranked #999.

Atomi Financial Group first reported a position in NBIX in Q2 2025 and has held it in 5 quarters since. 780 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Atomi Financial Group held 1,888 shares of Neurocrine Biosciences worth $318K as of Q2 2026.
  • Atomi Financial Group bought 112 Neurocrine Biosciences shares in Q2 2026, an estimated $16.6K.
  • Neurocrine Biosciences made up 0.01% of Atomi Financial Group's portfolio in Q2 2026, its #999 holding.
  • Atomi Financial Group first reported a position in Neurocrine Biosciences in Q2 2025 and has held it in 5 quarters since.
  • 780 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Atomi Financial Group's 13F filing for Q2 2026, filed 4 Aug 2026.